

Third Annual ISSPP Congress 2022

 [WELCOME!](#) [GENERAL INFORMATION](#)

- Safety Protocols & Check-in
- Conference Details: Location, Times, etc.

 [CONFERENCE INFORMATION](#)

- Credit Information

 [E-SYLLABUS](#) [WIFI INFORMATION](#) [MEET THE FACULTY RECEPTION](#) [ACKNOWLEDGMENT OF EXHIBIT & SPONSORSHIP SUPPORT](#) [CORE COMPETENCIES INFORMATION SHEET](#) [DISCLOSURES](#) [SCHEDULE](#)

- Conference Schedule
- LATAM PIPAC Session
- Poster Sessions

 [CONFERENCE TASKS](#)

- Link to Evaluation & Conference Feedback Survey



Third Annual ISSPP Congress 2022

Welcome to the Third Annual ISSPP Congress 2022, in Huntington Beach, CA!

On behalf of City of Hope and the Department of Continuing Medical Education, we would like to thank you for joining us for this educational activity.

Congress Highlights Include:

- Multidisciplinary approaches to colorectal, appendiceal, ovarian, gastric, and thoracic metastases
- Networking opportunities amongst clinicians, investigators and scientists across institutions and geographical borders

Our goal is to provide the desired information and skills which physicians and allied health care providers need in order to better serve their patient populations and research. Your thoughts are valuable and important, so please share them with us on the evaluation that will be emailed to you at the conclusion of the conference.

Should you have any questions, please visit the conference staff at the registration desk.

For post-conference CME information, please contact:

City of Hope
Department of Continuing Medical Education
1500 E. Duarte Road, Bldg. #175
Duarte, CA 91010
cme@coh.org
(626) 218-5622



◆ General Information ◆

Third Annual ISSPP Congress 2022

SAFETY PROTOCOLS

RECOMMENDED: Masks are recommended in all conference space areas.

To ensure masks are effective, it is suggested to always wear masks correctly over your nose and mouth in all conference space areas. If you do not have a mask and would like one, please visit the registration desk.

ADDITIONAL SAFETY PROTOCOLS:

Providing a safe environment for all participants is our top priority.

The following safeguards are currently in effect to help ensure everyone feels as safe as possible during the live workshop:

1. Hand sanitizer will be made readily available.
2. Frequent cleaning of all conference areas.
3. It is recommended that no food be brought into the workshop meeting space.
4. Only pre-registered attendees will be allowed in the workshop areas. No visitors (guests, friends or family), or walk in/same day registrations will be allowed.
5. Conference badge must be worn at all times. If you misplace your badge, you will not be able to enter the conference area due to the safety protocols in place.

CONTACTLESS REGISTRANT SIGN-IN:

You must confirm your attendance **every day** at the conference, by checking in at the registration desk.



◆ General Information ◆

Third Annual ISSPP Congress 2022

MEETING MATERIALS

Check-in at the registration desk to receive conference materials and a name badge.

CONFERENCE NAME BADGE

Official conference name badge **must** always be worn to gain and maintain access to conference room and meals.

CONFERENCE LOCATION

Paséa Hotel & Spa
21080 Pacific Coast Highway
Huntington Beach, CA 92648

EDUCATIONAL SESSION

Sapphire Ballroom

REGISTRATION DESK | HOURS OF OPERATION

DATE	TIME	LOCATION
Thursday, October 13, 2022	6:30 AM – 6:15 PM	Sapphire Ballroom Foyer
Friday, October 14, 2022	6:30 AM – 6:30 PM	Sapphire Ballroom Foyer

CONGRESS MEALS

DATE	DESCRIPTION	TIME	LOCATION
Thursday, October 13	Breakfast	6:30 – 7:30 AM	Sapphire Ballroom
Thursday, October 13	Refreshment Break	10:15 – 10:45 AM	Sapphire Ballroom
Thursday, October 13	Lunch	12:15 – 1:15 PM	Sapphire Ballroom
Thursday, October 13	Refreshment Break	3:15 – 3:45 PM	Sapphire Ballroom
Thursday, October 13	<i>Meet the Faculty Reception</i>	6:15 – 8:00 PM	Ocean Lawn
Friday, October 14	Breakfast	6:30 – 7:20 AM	Sapphire Ballroom
Friday, October 14	Refreshment Break	9:00 – 9:30 AM	Sapphire Ballroom
Friday, October 14	Lunch	12:00 – 1:00 PM	Sapphire Ballroom
Friday, October 14	Refreshment Break	3:00 – 3:30 PM	Sapphire Ballroom

EXHIBIT HALL & POSTER SESSIONS | HOURS OF OPERATION

DATE	TIME	LOCATION
Thursday, October 13	6:30 – 7:30 AM	Sapphire Ballroom
Thursday, October 13	10:15 – 10:45 AM	Sapphire Ballroom
Thursday, October 13	12:15 – 1:15 PM	Sapphire Ballroom
Thursday, October 13	3:15 – 3:45 PM	Sapphire Ballroom
Friday, October 14	6:30 – 7:20 AM	Sapphire Ballroom
Friday, October 14	9:00 – 9:30 AM	Sapphire Ballroom
Friday, October 14	12:00 – 1:00 PM	Sapphire Ballroom
Friday, October 14	3:00 – 3:30 PM	Sapphire Ballroom



◆ Conference Information ◆

Third Annual ISSPP Congress 2022

Accreditation Statement

City of Hope is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement

City of Hope designates this live activity for a maximum of 17.25 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the educational activity.

The following may apply *AMA PRA Category 1 Credit™* for license renewal:

- **Registered Nurses:** Nurses may report up to 17.25 credit hours toward the continuing education requirements for license renewal by their state Board of Registered Nurses (BRN). CME may be noted on the license renewal application in lieu of a BRN provider number.
- **Physician Assistants:** The National Commission on Certification of Physician Assistants states that *AMA PRA Category 1 Credit™* accredited courses are acceptable for continuing medical education requirements for recertification.

Disclosure

This activity has been planned and implemented in strict compliance with the accreditation requirements, standards and policies of the ACCME. City of Hope takes responsibility for the content, quality and scientific integrity of this CME activity. Faculty and Planners have provided written disclosure of all relevant commercial relationships which have been included in this handout. Any potential conflicts relative to the disclosure(s) have been resolved. City of Hope further encourages faculty/presenters to identify investigational products or off-label uses of products regulated by the U.S. Food and Drug Administration at first mention and where appropriate in the content. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Credit Transcripts will be updated within a week to reflect your participation in this conference.

Retrieve your CME Transcripts by visiting the City of Hope CME website: <https://cme.cityofhope.org/>
Login using your registered Email and Password.

Quick Tip!

Have trouble remembering your password? Once you log in to your account, do not log out, so you do not have to log back in!

Once logged in, click on the My Transcripts section at the top of the page, and click on "Completed Activities". You can then print your Credit Transcript or the individual Certificate, if desired.

For assistance, contact the Department of Continuing Medical Education at 626-218-5622 or cme@coh.org.

Third Annual ISSPP Congress 2022

To ensure that you are receiving the most current slide sets presented, as well as keeping with City of Hope's "green initiative" to reduce waste, an e-syllabus containing slide sets is available for this activity online only (**printed presentation not available on-site**). We recommend you access available presentations prior to the conference and bring your computer or mobile device fully charged. We gratefully acknowledge the presenters for their permission to offer this material as an e-syllabus.

E-Syllabus Download/Printing Instructions: *(printed syllabus will not be provided on-site)*

If you would like to download or print a copy of available presentations simply:

1) Visit the following link:

<https://cme.cityofhope.org/content/third-annual-isspp-congress-2022-e-syllabus>

2) Find the desired presentation and click on the title of the presentation you would like to download

3) The presentation will open and appear in PDF format

4) To save the presentation, click "Save As"

5) To print the presentation, click "Print"

AJCC Cancer Staging Forms

- Access to the AJCC Cancer Staging Forms is also available via the e-syllabus.

PLEASE NOTE:

- ❖ Some presentations not provided prior to the conference will be accessible post-activity.
- ❖ All presentations will be available for 4 weeks following the conclusion of this educational activity.
- ❖ Presentations have been uploaded at the discretion of each faculty member.

Third Annual ISSPP Congress 2022

Wi-Fi Network

“Pasea Wireless”

(NO PASSWORD NECESSARY)

THIRD ANNUAL

ISSPP Congress 2022

*International Society for the
Study of Pleura and Peritoneum*





◆ General Information ◆

Third Annual ISSPP Congress 2022

You're invited!

Meet the Faculty Reception

Thursday, October 13, 2022



OCEAN LAWN
6:15 – 8:00 PM

Registered attendees are invited to attend the Meet the Faculty Reception.

To comply with restrictions, no visitors/guests will be permitted.

Conference badge must be worn for admittance.



Acknowledgment of Exhibit Support

City of Hope gratefully acknowledges the generous support from:

AADI BIOSCIENCE
ACPMP RESEARCH FOUNDATION
AMGEN
ASTRAZENECA
BAYER PHARMACEUTICALS
BRISTOL MYERS SQUIBB
CAPNOPHARM GMBH
CHOLANGIOCARCINOMA FOUNDATION
CITY OF HOPE PHYSICIAN RELATIONS
COHERUS BIOSCIENCES
DAIICHI SANKYO, INC.
GSK
GUARDANT HEALTH
HOPE FOR STOMACH CANCER
IPSEN BIOPHARMACEUTICALS
KITE PHARMA
MERCK & CO., INC.
PMP PALS
SEAGEN
SERVIER PHARMACEUTICALS
TERSERA
YUMANTIS



Sponsorship Acknowledgment

City of Hope gratefully acknowledges the generous sponsorship from:

Conference Sponsors

IMUGENE

NORTHGATE TECHNOLOGIES, INC.

THERMASOLUTIONS

Welcome Sponsor

REGER MEDIZINTECHNIK GMBH



Unrestricted Educational Grant

City of Hope gratefully acknowledges the generous support from:

APPLIED MEDICAL

CORE COMPETENCIES INFORMATION SHEET

PRACTICE-BASED LEARNING AND IMPROVEMENT

Physicians must be able to investigate and evaluate their patient care practices, appraise and assimilate scientific evidence, and improve their patient care practices. **CME programs address these issues if the topics relate to:**

- analyzing practice experience and performing practice-based improvement activities using a systematic methodology
- locating, appraising, and assimilating evidence from scientific studies related to their patients' health problems
- obtaining and using information about their own population of patients and the larger population from which their patients are drawn
- applying knowledge of study designs and statistical methods to the appraisal of clinical studies and other information on diagnostic and therapeutic effectiveness
- using information technology to manage information, access on-line medical information; and support their own education
- facilitating the learning of students and other health care professionals

PATIENT CARE

Physicians must be able to provide patient care that is compassionate, appropriate, and effective for the treatment of health problems and the promotion of health. **CME programs address these issues if they address topics related to:**

- The ability to communicate effectively and demonstrate caring and respectful behaviors when interacting with patients and their families;
- gathering essential and accurate information about their patients
- making informed decisions about diagnostic and therapeutic interventions based on patient information and preferences, up-to-date scientific evidence, and clinical judgment
- developing and carrying out patient management plans
- counseling and educating patients and their families
- using information technology to support patient care decisions and patient education
- performing competently all medical and invasive procedures considered essential for the area of practice
- providing health care services aimed at preventing health problems or maintaining health
- working with health care professionals, including those from other disciplines, to provide patient-focused care

SYSTEMS-BASED PRACTICE

Physicians must demonstrate an awareness of and responsiveness to the larger context and system of health care and the ability to effectively call on system resources to provide care that is of optimal value. **CME programs address these issues if the topics relate to:**

- understanding how their patient care and other professional practices affect other health care professionals, the health care organization, and the larger society and how these elements of the system affect their own practice
- knowing how types of medical practice and delivery systems differ from one another, including methods of controlling health care costs and allocating resources
- practicing cost-effective health care and resource allocation that does not compromise quality of care
- advocating for quality patient care and assisting patients in dealing with system complexities
- knowing how to partner with health care managers and health care providers to assess, coordinate, and improve health care and knowing how these activities can affect system performance

MEDICAL KNOWLEDGE

Physicians must demonstrate knowledge about established and evolving biomedical, clinical, and cognate (e.g. epidemiological and social-behavioral) sciences and the application of this knowledge to patient care. **CME programs address these issues if the topics relate to:**

- demonstration of an investigatory and analytic thinking approach to clinical situations
- knowledge and application of the basic and clinically supportive sciences which are appropriate to their discipline

INTERPERSONAL AND COMMUNICATION SKILLS

Physicians must be able to demonstrate interpersonal and communication skills that result in effective information exchange and teaming with patients, their patients families, and professional associates. **CME programs address these issues if the topics relate to:**

- creating and sustaining a therapeutic and ethically sound relationship with patients
- using effective listening skills and eliciting and providing information using effective nonverbal, explanatory, questioning, and writing skills
- working effectively with others as a member or leader of a health care team or other professional group

PROFESSIONALISM

Physicians must demonstrate a commitment to carrying out professional responsibilities, adherence to ethical principles, and sensitivity to a diverse patient population. **CME programs address these issues if the topics relate to:**

- demonstrating respect, compassion, and integrity; responsiveness to the needs of patients and society that supersedes self-interest; accountability to patients, society, and the profession; and a commitment to excellence and on-going professional development
- demonstrating a commitment to ethical principles pertaining to provision or withholding of clinical care, confidentiality of patient information, informed consent, and business practices
- demonstrating sensitivity and responsiveness to patients' culture, age, gender, and disabilities

◆ Department of Continuing Medical Education ◆

Conflict of Interest Disclosure and Resolution & Core Competencies
Third Annual ISSPP Congress 2022
October 13-14, 2022

City of Hope takes responsibility for the content, quality, and scientific integrity of this CME activity.

City of Hope is accredited by the Accreditation Council for Continuing Medical Education (ACCME). As a fully accredited ACCME Category 1 CME credit provider, the Continuing Medical Education Department has in place policies and procedures which insure the balance, independence, objectivity and scientific rigor in all of its educational activities. City of Hope complies with the [Standards for Integrity and Independence in Accredited Continuing Education](#) of the (ACCME), which REQUIRE that all relevant disclosed conflicts of interest be mitigated prior to the educational activity.

To this end all faculty presenters who are in a position to control the content of an educational activity must identify any real or apparent conflict(s) of interest by disclosing to the Department of CME all relevant financial relationships¹ with any ineligible company². To comply with more intense scrutiny by accreditation agencies, should you disclose any relevant conflict of interest with an ineligible company, the content of your presentation must be peer reviewed prior to presenting. Presentations will be provided to participants as an e-syllabus or in a meeting handout, all relevant disclosures will be made known to participants prior to the start of the activity.

In furtherance of program impartiality, we request the use of generic drug names in your presentation as opposed to trade names. Under no circumstances will we accept trade names. Additionally, contents of your presentation must be based solely on scientific methods generally accepted by the medical community. Data will have been objectively selected from peer-reviewed literature and will be presented in an unbiased manner.

CORE COMPETENCIES

The American Board of Medical Specialties (ABMS) and the Accreditation Council of Graduate Medical Education (ACGME) have embarked on a joint initiative to quantify and evaluate a set of 6 physician core competencies by which the individual physician will be measured for Residency Certification, Board Certification and more recently, Maintenance of Certification (MOC). Individual hospitals and other health care delivery organizations will now also be evaluated by the Joint Commission on Accreditation of Healthcare Organizations (JCAHO) on their practice and demonstration of the 6 core competencies.

In brief, the actual term “core competencies” refers to those six abilities (competencies) that are central (core) to the practice of medicine, specifically: (1) Practice-Based Learning and Improvement, (2) Patient Care, (3) Systems-Based Practice, (4) Medical Knowledge, (5) Interpersonal and Communication Skills, and (6) Professionalism. To assist our conferees in demonstrating their completion of CME in the six core competencies, the educational content of each presentation will be noted by numbers 1-6 in the table below. CME certificates for this activity will reflect those core competencies addressed by the educational content of the overall conference.

Conference Faculty	Commercial Interest	Conflict/ Resolution & Faculty Discussion of Off-Label Drugs	Core Competencies
Prasad S. Adusumilli, MD	Grant/Research Support from Atara Biotherapeutics; Consultant for Atara Biotherapeutics, Bayer, BioArdis, Imugene, and Johnson & Johnson. Other financial material interests in Atara Biotherapeutics.	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted.	1, 2 & 4
Mohammad Alyami, MD	I do not have any relevant financial relationships with any ineligible companies.	None <i>Off-label/Investigational use of: Cisplatin and Doxorubicin</i>	1, 2, 3, 4, 5 & 6
Brian Badgwell, MD, MS	I do not have any relevant financial relationships with any ineligible companies.	None	1
Naoual Bakrin, MD, PhD	Consultant for GlaxoSmithKline.	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted. <i>Off-label/Investigational use of: Cisplatin and Doxorubicin</i>	1, 2 & 4
Lana Bijelic, MD	I do not have any relevant financial relationships with any ineligible companies.	None	Moderator
Wilbur Bo Bowne, MD	I do not have any relevant financial relationships with any ineligible companies.	None	2 & 4

Conference Faculty	Commercial Interest	Conflict/ Resolution & Faculty Discussion of Off-Label Drugs	Core Competencies
Andreas Brandl, MD, PhD	I do not have any relevant financial relationships with any ineligible companies.	None	Delphi Results
Wim P. Ceelen, MD, PhD	I do not have any relevant financial relationships with any ineligible companies.	None <i>Off-label/Investigational use of: Abraxane, & OniVyde</i>	2 & 4
Joseph Chao, MD	Grant/Research Support from Merck; Consultant for Amgen, Astellas, AstraZeneca, Merck, and Roche; On the Speakers Bureau for Bristol Myers Squibb, and Merck.	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted.	1, 2, 3, 4, 5 & 6
Ernest Cheng, MD	I do not have any relevant financial relationships with any ineligible companies.	None <i>Off-label/Investigational use of: Bromelain and N-acetylcysteine</i>	2 & 4
Vincent Chung, MD	On the Speakers Bureau for AstraZeneca, and Ipsen; Consultant for Pfizer.	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted.	4
Delia Cortés-Guiral, MD, PhD	I do not have any relevant financial relationships with any ineligible companies.	None	1 & 4
Thanh H. Dellinger, MD	I do not have any relevant financial relationships with any ineligible companies.	None	Moderator
Jesse Demuytere, MD	I do not have any relevant financial relationships with any ineligible companies.	None	Plenary Abstract
Danielle K. DePeralta, MD	I do not have any relevant financial relationships with any ineligible companies.	None	Moderator
Jacopo Desiderio, MD, PhD	I do not have any relevant financial relationships with any ineligible companies.	None	1, 2, 3 & 4
Sönke Detlefsen, MD, PhD	I do not have any relevant financial relationships with any ineligible companies.	None	4
Jesus Esquivel, MD	I do not have any relevant financial relationships with any ineligible companies.	None	1, 2 & 4
Clarisse Eveno, MD, PhD	I do not have any relevant financial relationships with any ineligible companies.	None	Plenary Abstract
Marwan G. Fakih, MD	Consultant for Amgen, AstraZeneca, Bayer, GlaxoSmithKline, Mirati Therapeutics, Pfizer, PsiOxus Therapeutics, Roche/Genentech, and Taiho Oncology; On the Speakers Bureau for Guardant 360.	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted.	4
Kjersti Flatmark, MD, PhD	Grant/Research Support from Bayer.	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted.	1 & 4
Christina Fotopoulou, MD, PhD	Consultant for AstraZeneca, Ethicon, GlaxoSmithKline, MSD, Roche, and Tesaro.	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted.	1, 2, 3, 4, 5 & 6
Alexandra Gangi, MD	I do not have any relevant financial relationships with any ineligible companies.	None	Moderator
Olivier Glehen, MD, PhD	Consultant for Gamida Cell.	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted.	1, 2, 4 & 5

Conference Faculty	Commercial Interest	Conflict/ Resolution & Faculty Discussion of Off-Label Drugs	Core Competencies
Céline Gongora, PhD	I do not have any relevant financial relationships with any ineligible companies.	None	Plenary Abstract
Martin Graversen, MD, PhD	I do not have any relevant financial relationships with any ineligible companies.	None	Plenary Abstract
Travis E. Grotz, MD	I do not have any relevant financial relationships with any ineligible companies.	None <i>Off-label/Investigational use of: Cisplatin, Mitomycin C, Nab-paclitaxel</i>	1, 2 & 4
Martin Hübner, MD	Grant from Capnomed; Consultant for Encare.	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted.	1, 2, 4 & 6
Hironori Ishigami, MD, PhD	Grant/Research Support from Chugai Pharmaceutical Co., Ltd. and Taiho Pharmaceutical Co, Ltd.	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted. <i>Off-label/Investigational use of: Paclitaxel</i>	1, 2 & 4
Pashtoon Kasi, MD, MS	Consultant for Bayer, Daiichi Sankyo, Inc., Eisai, Exact Sciences, Foundation Medicine, Lilly, Merck, Natera, Servier, and Taiho Pharmaceutical Co, Ltd.	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted.	1, 2, 3, 4, 5 & 6
Samuel J. Klempner, MD	Consultant for AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, Eli Lilly, and Merck.	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted.	2 & 4
Robert S. Krouse, MD	I do not have any relevant financial relationships with any ineligible companies.	None	1, 2, 3, 4 & 5
Ulrich M. Lauer, MD	Consultant for Amgen, Ipsen, & ViraTherapeutics.	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted. <i>Off-label/Investigational use of: OLV1-VEC (formerly denominated as GL-ONC1) (Genelux, San Diego, CA)</i>	1, 2, 4 & 6
Edward A. Levine, MD	I do not have any relevant financial relationships with any ineligible companies.	None	2 & 4
Daneng Li, MD	Grant/Research Support from AstraZeneca; Consultant for Delcath Systems, Inc., Eisai, Genentech, Ipsen, and Merck.	Attestation on file – No conflict noted	Moderator & Reviewer
Faheez Mohamed, MD	I do not have any relevant financial relationships with any ineligible companies.	None	1, 2, 3, 4, 5 & 6
Amit Merchea, MD	I do not have any relevant financial relationships with any ineligible companies.	None	Moderator
Michael Bau Mortensen, MD, PhD	I do not have any relevant financial relationships with any ineligible companies.	None	1 & 2
I. Benjamin Paz, MD, MS	I do not have any relevant financial relationships with any ineligible companies.	None	Moderator
Marc Pocard, MD, PhD	Grant/Research Support from Bristol Myers Squibb, CAPNOMED GmbH, and Pierre Fabre; Consultant for Gamida, LEO Pharm, and Roche.	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted.	1, 2, 3, 4, 5 & 6 Plenary Abstract

Conference Faculty	Commercial Interest	Conflict/ Resolution & Faculty Discussion of Off-Label Drugs	Core Competencies
Saul Priceman, PhD	Consultant for Celularity, Imugene, and Mustang Bio.	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted. <i>Off-label/Investigational use of: CAR T Cells</i>	4
Robert Ramsay, PhD	Grant/Research Support from Merck.	Attestation on file – No conflict noted	Moderator
Mustafa Raoof, MD, MS	I do not have any relevant financial relationships with any ineligible companies.	None <i>Off-label/Investigational use of: Mitomycin C, Abraxane (Nab-Paclitaxel), Oxaliplatin, 5-FU, Cisplatin, Doxorubicin</i>	1, 3 & 4
Pascal Rousset, MD, PhD	I do not have any relevant financial relationships with any ineligible companies.	None	1
Camilla Row	I do not have any relevant financial relationships with any ineligible companies.	None	Patient
Valerie W. Rusch, MD	Grant/Research Support from Genentech.	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted.	1, 2 & 4
Crystal Saavedra, BA	I do not have any relevant financial relationships with any ineligible companies.	None	Planner
Somashekhar S P, MCh	I do not have any relevant financial relationships with any ineligible companies.	None	1, 3 & 4
Hooman Salavati, MSc	I do not have any relevant financial relationships with any ineligible companies.	None	Plenary Abstract
Ravi Salgia, MD, PhD	Consultant for AstraZeneca and Sanofi; On the Speakers Bureau for AstraZeneca and Sanofi.	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted. <i>Off-label/Investigational use of: CAR T Cells</i>	1, 2, 3, 4, 5 & 6
Olivia Sgarbura, MD, PhD	I do not have any relevant financial relationships with any ineligible companies.	None <i>Off-label/Investigational use of: Cisplatin Doxorubicin as PIPAC Immunotherapy for MPM</i>	1, 2, 4, 5 & 6
Jimmy B.Y. So, MBChB, MPH	I do not have any relevant financial relationships with any ineligible companies.	None	1, 2, 3, 4, 5 & 6
Wiebke Solass, MD	Other financial/material interests in Capnopharm GmbH (royalties).	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted.	4 Plenary Abstract
Daphne Stewart, MD, MS	I do not have any relevant financial relationships with any ineligible companies.	None	1, 2, 3 & 4
Beatrice Sun, MD	I do not have any relevant financial relationships with any ineligible companies.	None	Plenary Abstract
Virginia Sun, PhD, RN	I do not have any relevant financial relationships with any ineligible companies.	None	2 & 5
Raghav Sundar, MBBS, PhD	Grant/Research Support from MSD; Consultant for Bayer, Bristol Myers Squibb, Eisai, Merck, and MSD.	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted.	1, 2, 3 & 4
Senthil Sundaram, BS	I do not have any relevant financial relationships with any ineligible companies.	None	Patient

Conference Faculty	Commercial Interest	Conflict/ Resolution & Faculty Discussion of Off-Label Drugs	Core Competencies
Kiran K. Turaga MD, MPH	I do not have any relevant financial relationships with any ineligible companies.	None	1, 2, 3 & 4
Erena van der Heijden	I do not have any relevant financial relationships with any ineligible companies.	None	Patient
Willemien J. van Driel, MD, PhD	I do not have any relevant financial relationships with any ineligible companies.	None	1 & 2
Konstantinos Votanopoulos, MD, PhD	I do not have any relevant financial relationships with any ineligible companies.	None	1, 2, 3 & 4
Richard L. Whelan, MD	I do not have any relevant financial relationships with any ineligible companies.	None	Moderator
Yanghee Woo, MD	Consultant for J&J Ethicon, and Imugene, LTD.	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted. <i>Off-label/Investigational use of: Oncolytic Viruses, and CAR-T Cell in clinical trials</i>	1, 3 & 4
Wei Peng Yong, MBChB	On the Speakers Bureau for Bristol Myers Squibb, Eisai, Lilly, and MSD; Consultant for Amgen, and AstraZeneca.	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted. <i>Off-label/Investigational use of: Paclitaxel, 5FV, Oxaliplatin, Asplatin</i>	2, 3 & 4

1. The ACCME defines "relevant" financial relationships" as financial relationships with an ineligible company (in any amount), occurring within the past 24 months, that create a conflict of interest.
2. The ACCME defines an "Ineligible company" as any entity producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Third Annual ISSPP Congress 2022

THURSDAY, OCTOBER 13, 2022

- 6:30 - 7:30 AM **REGISTRATION / BREAKFAST / EXHIBITS/ POSTER SESSIONS**
- 7:30 – 7:45 AM **Opening Ceremony**
- 7:45 - 8:15 AM **Keynote Lecture**
Primary and Metastatic Pleural Malignancies
Valerie W. Rusch, MD
- 8:15 – 9:15 AM **SESSION I | PERITONEAL ASSESSMENT**
Moderators: Amit Merchea, MD & Wiebke Solass, MD
- Pathology: PRGS and Its Value for Response Assessment and Prognosis | *Sönke Detlefsen, MD, PhD*
 - Radiology – Modified RECIST Criteria for Peritoneal Response | *Pascal Rousset, MD, PhD*
 - Laparoscopic Assessment of the Peritoneum | *Kiran K. Turaga, MD, MPH*
 - Molecular Landscape of Peritoneal Metastases: Biomarkers and Therapeutic Targets | *Raghav Sundar, MBBS, PhD*
- Panel Discussion*
- 9:15 - 10:15 AM **SESSION II | TREATMENT MODALITIES**
Moderators: Delia Cortés-Guiral, MD, PhD & Marc Pocard, MD, PhD
- Current Landscape of Peritoneal Treatments | *Martin Hübner, MD*
 - Rationale for Regional Therapies | *Mustafa Raoof, MD, MS*
 - Role of Immunotherapies in Peritoneal Metastases | *Samuel J. Klempner, MD*
- Panel Discussion*
- 10:15 - 10:45 AM **REFRESHMENT BREAK / EXHIBITS/ POSTER SESSIONS**
- 10:45 - 11:45 AM **SESSION III | NOVEL THERAPEUTIC AGENTS FOR PLEURA & PERITONEAL CANCERS**
Moderator: Yanghee Woo, MD & Robert Ramsay, PhD
- CAR T-Cell Therapy for Pleural and Peritoneal Cancers | *Prasad S. Adusumilli, MD*
 - Translational Intraperitoneal Immunotherapeutic Strategies Targeting Tumor-Associated Antigens
Wilbur Bo Bowne, MD
 - Oncolytic Viruses and Combination Immunotherapy Strategies for GI Peritoneal Carcinomatosis
Ulrich M. Lauer, MD
 - CAR T-Cell Engineering and Combination Therapies for the Treatment of Ovarian Cancer | *Saul Priceman, PhD*
- Panel Discussion*
- 11:45 AM - 12:15 PM **CONSENSUS ON OPTIMAL ENDPOINTS IN PSM**
Olivia Sgrabrava, MD, PhD; Martin Hübner, MD; Andreas Brandl, MD, PhD; Thanh H. Dellinger, MD; Yanghee Woo, MD & Mustafa Raoof, MD, MS
- 12:15 - 1:15 PM **LUNCH / EXHIBITS/ POSTER SESSIONS**
- 1:15 - 3:15 PM **SESSION IV | APPENDICEAL CANCERS**
Moderators: Lana Bijelic, MD & Richard L. Whelan, MD
- Molecular and Histologic Classification of Appendiceal Neoplasms | *Edward A. Levine, MD*
 - Pushing the Boundaries of Surgical Resection in Appendiceal Cancers | *Faheez Mohamed, MD*
 - Tackling Recurrence: Peptide Vaccines in the Treatment of PMP | *Kjersti Flatmark, MD, PhD*

Third Annual ISSPP Congress 2022

THURSDAY, OCTOBER 13, 2022 (continued)

1:15 - 3:15 PM **SESSION IV | APPENDICEAL CANCERS** (continued)

- Updates and Lessons from the BromAc Trial | *Ernest Cheng, MD*
- *Plenary Abstract*: Influence of the Peritoneal Metastatic Microenvironment on Interstitial Permeability | *Hooman Salavati, MSc*
- *Plenary Abstract*: Combination of Antiangiogenic Antibiotic Treatments Inhibits the Growth of Pseudomyxoma Peritonei In Vivo in a Mouse Model | *Marc Pocard, MD, PhD*
- Panel Discussion
- Moderated Cases 1 & 2
Wrap Up

3:15 - 3:45 PM

REFRESHMENT BREAK / EXHIBITS/ POSTER SESSIONS

3:45 - 5:45 PM

SESSION V | COLORECTAL CANCERS

Moderators: Alexandra Gangi, MD & Mustafa Raoof, MD, MS

- Systemic Approaches to Colorectal Peritoneal Metastases | *Pashtoon Kasi, MD, MS*
- Regional Approaches: Moving Beyond PRODIGE 7 | *Wim P. Ceelen, MD, PhD*
- Organoids in Precision Medicine in Peritoneal Metastases | *Konstantinos Votanopoulos, MD, PhD*
- *Plenary Abstract*: A Single-cell Resolution Landscape of Peritoneal Metastases of Colorectal Cancer | *Jesse Demuytere, MD*
- *Plenary Abstract*: Combination of oxaliplatin+ATRI+anti-PD1+for treatment of peritoneal metastasis of colorectal origin is highly effective | *Céline Gongora, PhD*
- *Panel Discussion*
- Moderated Case 1 & 2
Wrap Up

First Great Debate

5:45 - 6:15 PM

Is There a Role for Regional Therapy in Colorectal Cancer?

Olivier Glehen, MD, PhD (PRO) vs. Marwan G. Fakih, MD (CON)
Discussion

6:15 PM

ADJOURN FOR THE DAY

6:15 – 8:00 PM

MEET THE FACULTY RECEPTION

Third Annual ISSPP Congress 2022

FRIDAY, OCTOBER 14, 2022

- 6:30 - 7:20 AM **REGISTRATION / BREAKFAST / EXHIBITS/ POSTER SESSIONS**
- 7:20 – 7:30 AM **Welcome & Announcements**
- 7:30 - 8:00 AM **Keynote Lecture**
Primary & Metastatic Peritoneal Malignancies
Delia Cortés-Guiral, MD, PhD
- 8:00 – 9:00 AM **SESSION VI | PLEURAL & PERITONEAL MESOTHELIOMA**
Moderators: I. Benjamin Paz, MD, MS & Olivia Sgarbura, MD, PhD
- Update on Treatment Approaches to Pleural Mesothelioma | *Ravi Salgia, MD, PhD*
 - Surgical Management of Peritoneal Malignant Mesothelioma | *Jesus Esquivel, MD*
 - Innovative Approaches and Clinical Trials for Peritoneal Malignant Mesothelioma
Olivia Sgarbura, MD, PhD
 - *Plenary Abstract: Tumor Microenvironment in Peritoneal Mesothelioma Under Therapy* | *Wiebke Solass, MD*
Panel Discussion
- 9:00 - 9:30 AM **REFRESHMENT BREAK / EXHIBITS/ POSTER SESSIONS**
- 9:30 – 10:00 AM **AWARDS & RECOGNITIONS**
- 10:00 – 11:30 AM **SESSION VII | OVARIAN CANCER**
Moderators: Thanh H. Dellinger, MD
- Patient Selection and Timing of HIPEC in Ovarian Cancer | *Naoual Bakrin, MD, PhD*
 - Histologic and Molecular Implications on Ovarian Cancer Treatment | *Wiebke Solass, MD*
 - How Do IP Chemotherapies Fit in with Systemic Therapies in Ovarian Cancer? | *Daphne Stewart, MD, MS*
 - Patient Selection and Timing of PIPAC in Ovarian Cancer | *Somashekhar S P, MCh*
 - *Plenary Abstract: Safety of Cytoreductive Surgery with Heated Intraperitoneal Gemcitabine and Systemic Dacarbazine for Recurrent Uterine Leiomyosarcoma – Preliminary Results of a Phase 2 Trial* |
Beatrice Sun, MD
Panel Discussion
Wrap Up
- 11:30 AM - 12:00 PM **The Next Great Debate**
Is There a Role of Regional Therapies in Ovarian Cancer?
Willemien van Driel, MD, PhD (PRO) vs. Christina Fotopoulou, MD, PhD (CON)
Discussion
- 12:00 - 1:00 PM **LUNCH / EXHIBITS/ POSTER SESSIONS**
- 1:00 - 3:00 PM **SESSION VIII | GASTRIC CANCERS**
Moderators: Jimmy B.Y. So, MBChB, MPH & Yanghee Woo, MD
- Evolution of Systemic Therapy for Gastric Cancer Peritoneal Metastases | *Yanghee Woo, MD*
 - Role of Palliative Surgery in Gastric Cancer Peritoneal Carcinomatosis? | *Jacopo Desiderio, MD, PhD*
 - Regional Treatment Strategies for Peritoneal Metastases in Gastric Cancer | *Jimmy B.Y. So, MBChB, MPH*
 - Intraperitoneal Chemotherapy for Treatment and Prevention of Peritoneal Metastases of Gastric Cancer | *Hironori Ishigami, MD, PhD*

Third Annual ISSPP Congress 2022

FRIDAY, OCTOBER 14, 2022 (continued)

1:00 - 3:00 PM	<p>SESSION VIII GASTRIC CANCERS (continued)</p> <ul style="list-style-type: none">• Practice and Trials of Regional Therapy for Gastric Cancer in the U.S. <i>Brian Badgwell, MD, MS</i>• Rationale and Outcomes for PIPAC in Gastric Cancer <i>Mohammad Alyami, MD</i>• <i>Plenary Abstract: PIPAC EstoK 01: First Randomized and Multicenter Phase II Study on Doxorubicin/Cisplatin Pressurized IntraPeritoneal Aerosol Chemotherapy in Gastric Peritoneal Metastasis: First Results on Early Postoperative Outcomes</i> <i>Clarisse Eveno, MD, PhD</i>• <i>Late Breaking Plenary Abstract: Adjuvant PIPAC during Laparoscopic Gastrectomy in High-Risk Gastric Cancer Patients: A Multicentre Phase I Study</i> <i>Martin Graversen MD, PhD</i> <p><i>Panel Discussion</i></p> <ul style="list-style-type: none">• Moderated Case Discussion <p><i>Wrap Up</i></p>
3:00 - 3:30 PM	<p>REFRESHMENT BREAK / EXHIBITS/ POSTER SESSIONS</p>
3:30 - 4:00 PM	<p><u>Final Great Debate</u></p> <p>Is There a Role for Regional Therapy in Gastric Cancer? <i>Wei Peng Yong, MBChB (PRO) & Joseph Chao, MD (CON)</i> <i>Discussion</i></p>
4:00 - 5:00 PM	<p>SESSION IX HEPATIC PANCREATIC BILIARY (HPB) <i>Moderators: Danielle K. DePeralta, MD & Daneng Li, MD</i></p> <ul style="list-style-type: none">• Systemic Therapy Consideration in PDAC Peritoneal Metastases <i>Vincent Chung, MD</i>• Role of PIPAC in HPB Cancers <i>Michael Bau Mortensen, MD, PhD</i>• Cytoreductive Surgery and HIPEC for PDAC <i>Travis E. Grotz, MD</i> <p><i>Panel Discussion</i></p> <p><i>Wrap Up</i></p>
5:00 – 6:15 PM	<p>SESSION X QUALITY OF LIFE & SURGICAL PALLIATION <i>Moderators: Martin Hübner, MD & I. Benjamin Paz, MD, MS</i></p> <ul style="list-style-type: none">• Patient Testimonials Focused on Quality of Life Issues (Ovarian/ Gastric/Colorectal) <i>Erena van der Heijden, Camilla Row, & Senthil Sundaram, BS</i>• Frailty, Prehab and HIPEC/PIPAC <i>Marc Pocard, MD, PhD</i>• Clinical Trial Endpoints: Quality of Life in Peritoneal Disease <i>Robert S. Krouse, MD</i>• Innovations in Patient-Reported Outcomes and Patient-Generated Health Data <i>Virginia Sun, PhD, RN</i> <p><i>Panel Discussion</i></p> <p><i>Wrap Up</i></p>
6:15 - 6:30 PM	<p>CLOSING REMARKS</p>
6:30 PM	<p>ADJOURN</p>



◆ FOLLOWING SESSIONS ARE NOT CME ACCREDITED ◆

LATAM PIPAC SESSION

FRIDAY, OCTOBER 14, 2022 | EMERALD COVE

8:00 – 8:10 AM

Welcome & Introduction

Highlights:

Launch of PIPAC in LATAM: Pitfalls & Mistakes

What We Learned/Advantages in Emergent Countries

Alternatives to Devices & Health Care Systems

8:10 - 8:30 AM

LATAM Group 1. PIPAC PROJECT

Laura Lay MD (Argentina)

Associate Authors: Gianni, S; Taype, X

Neoadjuvant PIPAC Plus Systemic Chemotherapy with Carboplatin/Plaquitaxel & Bevacizumab for Ovarian, Tubal & Primary Peritoneal Carcinoma in Patients not Suitable for Primary CRS

8:30 – 8:50 AM

LATAM Group 2. PIPAC RESULTS

Mario Uribe, MD (Chile)

Associates: Uribe M; Perrotta, F; Sandoval J, Lay L; Gianni S; Melo, I; Delgadillo, X
PIPAC Initial Results in Colorectal-Pancreas Carcinomatosis

8:50 – 9:10 AM

LATAM Group 3. PIPAC BRIDGE TO CRS

Francisco Perrotta, MD, PhD (Paraguay)

Associates: Perrotta, F; Uribe, M; Sandoval J, Lay L; Gianni S; Delgadillo, X
Gastric PIPAC as a Bridge to HIPEC and CRS

9:10 – 9:30 AM

OTHER LATAM Groups/Consensus & Results

Chair: Xavier Delgadillo, MD, PhD (HON)

9:30 AM

ADJOURN



◆ POSTER SESSION ◆

Third Annual ISSPP Congress 2022

DON'T FORGET TO VISIT OUR POSTER HALL!

Thursday, October 13, 2022

6:30 – 7:30 AM

10:15 – 10:45 AM

12:15-1:15 PM

3:15 – 3:45 PM

Friday, October 14, 2022

6:30 – 7:20 AM

9:00 – 9:30 AM

12:00 – 1:00 PM

3:00 – 3:30 PM



◆ Conference Information ◆

Third Annual ISSPP Congress 2022

CONFERENCE TASKS:

We value your feedback! As part of the course, please complete the following tasks.

Conference Evaluation opens 10/14/2022 at 6:30pm:

<https://cme.cityofhope.org//node/7751/course-object/18924>

Conference Feedback opens 10/14/2022 at 6:30pm:

<https://cme.cityofhope.org//node/7751/course-object/18928>

IMPORTANT:

*Last day to complete Symposium Tasks is: **10/21/2022***



◆ Conference Information ◆

Third Annual ISSPP Congress 2022

**Thank you for participating in the
Third Annual ISSPP Congress 2022!**



A SPECIAL THANKS TO THE ISSPP FOR THEIR COLLABORATION!